Abstract Number: 2374 • 2012 ACR/ARHP Annual Meeting
Characteristics, Treatment and Outcome of Gastrointestinal Involvement in Behcet’s Syndrome: Experience in A Dedicated Center
Background/Purpose: Gastrointestinal involvement can be a severe complication resulting in perforation and massive bleeding. Controlled data regarding treatment is lacking and long term prognosis is…Abstract Number: 2376 • 2012 ACR/ARHP Annual Meeting
Behcet’s Disease: Combination of Pulse Cyclophosphamide, Azathioprine, and Prednisolone for the Treatment of Retinal Vasculitis; Longitudinal Study On 10 Years
Background/Purpose: Ocular lesions of Behcet’s Disease (BD), need aggressive treatment to prevent severe loss of vision or blindness. Cytotoxic drugs are the main therapeutic agents…Abstract Number: 1005 • 2012 ACR/ARHP Annual Meeting
The Identification of Pathway Markers in Behcet’s Disease Using Genomewide Association Data From Two Different Populations
Background/Purpose: Behcet's disease (BD) is a multi-system inflammatory disease, characterized by recurrent exacerbations affecting several organs including orogenital mucosa, eyes and skin. Two recent genome-wide…Abstract Number: 858 • 2012 ACR/ARHP Annual Meeting
Dense Genotyping, Imputation, and Regression Analysis Identifies Multiple Independent Genetic Susceptibility Loci within the HLA Region in Behcet’s Disease
Background/Purpose: The genetic association between HLA-B51 and Behcet’s disease is well established. However, localizing this genetic effect and exploring additional susceptibility loci within the HLA…Abstract Number: 203 • 2012 ACR/ARHP Annual Meeting
Clinical Course Factors Associated with Outcome of Monoarthritis : A Retrospective Study of 173 Cases
Background/Purpose: To evaluate the clinical features and outcomes in patients with monoarthritis and to investigate predictive factors associated with the clinical course in terms of…Abstract Number: 181 • 2012 ACR/ARHP Annual Meeting
Thiopurine S-Methyltransferase Levels in Patients with Behçet’s Disease
Background/Purpose: Azathioprine (AZA) is an immunosuppressive agent which is widely used not only for the treatment of Behcet’s disease (BD), but also for the treatment…Abstract Number: 183 • 2012 ACR/ARHP Annual Meeting
A Strong Association Between HLA-A*26 and Behçet’s Syndrome in Japanese Patients: From Two-Center Cohort Study of Behçet’s Syndrome
Background/Purpose: An association between Behçet’s Syndrome (BS) and HLA-B*51 is widely reported among many different ethnic groups. Recently, a few reports from Taiwan, Greece and…Abstract Number: 184 • 2012 ACR/ARHP Annual Meeting
The Retrospective Review of 39 Intestinal Behcet’s Disease Focusing On the Requirement for the Immunosuppresive Drugs Other Than Corticosteroid
Background/Purpose: To examine the demography, clinical characteristics, features of intestinal lesions, treatment, and prognosis in patients with the intestinal Behcet’s disease currently followed at a…Abstract Number: 185 • 2012 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Tumour Necrosis Factor Antagonists for Patients with Behçet’s Disease with Uveitis As Main Involvement
Background/Purpose: To assess the long-term efficacy and safety of tumour necrosis factor (TNF) antagonists (infliximab [IFX], adalimumab [ADA] and golimumab) for the treatment of patients…
- « Previous Page
- 1
- …
- 10
- 11
- 12